Moon S, Ruiz A, Vieira M, Large K, Slovenski I
J Pharm Policy Pract. 2025; 18(1):2436899.
PMID: 39830933
PMC: 11740976.
DOI: 10.1080/20523211.2024.2436899.
Vallano A, Pontes C
Front Public Health. 2024; 12:1449707.
PMID: 39381757
PMC: 11458516.
DOI: 10.3389/fpubh.2024.1449707.
Kliegman M, Zaghlula M, Abrahamson S, Esensten J, Wilson R, Urnov F
Nature. 2024; 634(8033):307-314.
PMID: 39019069
DOI: 10.1038/s41586-024-07800-7.
Zaprutko T, Cynar J, Sygit M, Stolecka A, Skorupska P, Jaszcz P
PLoS One. 2024; 19(6):e0304400.
PMID: 38848422
PMC: 11161061.
DOI: 10.1371/journal.pone.0304400.
Okpechi I, Luyckx V, Tungsanga S, Ghimire A, Jha V, Johnson D
Nephrol Dial Transplant. 2024; 39(11):1762-1771.
PMID: 38769588
PMC: 11648948.
DOI: 10.1093/ndt/gfae116.
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund.
Risse J, Krzemien M, Schnalke J, Heinemann T
Gene Ther. 2024; 31(7-8):353-357.
PMID: 38658672
PMC: 11257980.
DOI: 10.1038/s41434-024-00452-2.
Reply to Comment on "A Framework for Fair Pricing of Medicines".
Paulden M
Pharmacoeconomics. 2024; 42(5):607-609.
PMID: 38478252
DOI: 10.1007/s40273-024-01369-9.
Shaping the future of global access to safe, effective, appropriate and quality health products.
Ravinetto R, Henriquez R, Srinivas P, Bradley H, Coetzee R, Ochoa T
BMJ Glob Health. 2024; 9(1).
PMID: 38195155
PMC: 10807033.
DOI: 10.1136/bmjgh-2023-014425.
Improving cardiovascular outcomes for patients with heart failure in sub-Saharan Africa: conference proceedings of the 2022 Nigerian Cardiovascular Symposium.
Ilonze O, Hicks A, Atanda B, Abdou M, Onyekwelu C, Chukwu E
Cardiovasc J Afr. 2023; 34(2):121-128.
PMID: 37145711
PMC: 10512044.
DOI: 10.5830/CVJA-2023-016.
Introduction of managed entry agreements in Korea: Problem, policy, and politics.
Kim H, Godman B, Kwon H, Hong S
Front Pharmacol. 2023; 14:999220.
PMID: 37124231
PMC: 10133550.
DOI: 10.3389/fphar.2023.999220.
Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
Enzing J, Knies S, Engel J, IJzerman M, Sander B, Vreman R
Cost Eff Resour Alloc. 2022; 20(1):46.
PMID: 36045377
PMC: 9434877.
DOI: 10.1186/s12962-022-00383-y.
Barriers to COVID-19 Health Products in Low-and Middle-Income Countries During the COVID-19 Pandemic: A Rapid Systematic Review and Evidence Synthesis.
Boro E, Stoll B
Front Public Health. 2022; 10:928065.
PMID: 35937225
PMC: 9354133.
DOI: 10.3389/fpubh.2022.928065.
Taking Systems Thinking to the Global Level: Using the WHO Building Blocks to Describe and Appraise the Global Health System in Relation to COVID-19.
Borghi J, Brown G
Glob Policy. 2022; 13(2):193-207.
PMID: 35601655
PMC: 9111126.
DOI: 10.1111/1758-5899.13081.
European governments should align medicines pricing practices with global transparency norms and legal principles.
Perehudoff K
Lancet Reg Health Eur. 2022; 16:100375.
PMID: 35492963
PMC: 9046441.
DOI: 10.1016/j.lanepe.2022.100375.
Cost and consequences of using 7.1 % chlorhexidine gel for newborn umbilical cord care in Kenya.
Brown L, Martin A, Were C, Biswas N, Liakos A, DeAngelis E
BMC Health Serv Res. 2021; 21(1):1249.
PMID: 34794442
PMC: 8603569.
DOI: 10.1186/s12913-021-06971-7.
Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney.
Vanholder R, Annemans L, Bello A, Bikbov B, Gallego D, Gansevoort R
Clin Kidney J. 2021; 14(7):1719-1730.
PMID: 34221379
PMC: 8243275.
DOI: 10.1093/ckj/sfab070.
Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia.
Hasnida A, Kok M, Pisani E
BMJ Glob Health. 2021; 6(Suppl 3).
PMID: 34049935
PMC: 8166595.
DOI: 10.1136/bmjgh-2020-003663.
Integrative Review of Managed Entry Agreements: Chances and Limitations.
Dias C, Godman B, Gargano L, Azevedo P, Garcia M, Souza Cazarim M
Pharmacoeconomics. 2020; 38(11):1165-1185.
PMID: 32734573
DOI: 10.1007/s40273-020-00943-1.
